Autoimmune Diseases in Patients With Myotonic Dystrophy Type 2.

Hashimoto autoimmune thyroiditis antineutrophil cytoplasmic antibodies antinuclear antibodies autoimmune diseases myotonic dystrophy type 2 (DM2)

Journal

Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899

Informations de publication

Date de publication:
2022
Historique:
received: 30 04 2022
accepted: 20 06 2022
entrez: 4 8 2022
pubmed: 5 8 2022
medline: 5 8 2022
Statut: epublish

Résumé

Myotonic dystrophy type 2 (DM2) is a rare autosomal dominant multisystemic disease with highly variable clinical presentation. Several case reports and one cohort study suggested a significant association between DM2 and autoimmune diseases (AIDs). The aim of this study is to analyze the frequency and type of AIDs in patients with DM2 from the Serbian DM registry. A total of 131 patients with DM2 from 108 families were included, [62.6% women, mean age at DM2 onset 40.4 (with standard deviation 13) years, age at entering the registry 52 (12.8) years, and age at analysis 58.4 (12.8) years]. Data were obtained from Akhenaten, the Serbian registry for DM, and through the hospital electronic data system. Upon entering the registry, 35 (26.7%) of the 131 patients with DM2 had AIDs including Hashimoto thyroiditis (18.1%), rheumatoid arthritis, diabetes mellitus type 1, systemic lupus, Sjogren's disease, localized scleroderma, psoriasis, celiac disease, Graves's disease, neuromyelitis optica, myasthenia gravis, and Guillain-Barre syndrome. At the time of data analysis, one additional patient developed new AIDs, so eventually, 36 (28.8%) of 125 DM2 survivors had AIDs. Antinuclear antibodies (ANAs) were found in 14 (10.7%) of 63 tested patients, including 12 without defined corresponding AID (all in low titers, 1:40 to 1:160). Antineutrophil cytoplasmic antibodies (ANCAs) were negative in all 50 tested cases. The percentage of women was significantly higher among patients with AIDs (82.9% vs. 55.2%, AIDs were present in as high as 30% of the patients with DM2. Thus, screening for AIDs in DM2 seems reasonable. Presence of AIDs and/or ANAs may lead to under-diagnosis of DM2.

Identifiants

pubmed: 35923829
doi: 10.3389/fneur.2022.932883
pmc: PMC9341519
doi:

Types de publication

Journal Article

Langues

eng

Pagination

932883

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 Peric, Zlatar, Nikolic, Ivanovic, Pesovic, Petrovic Djordjevic, Sreckovic, Savic-Pavicevic, Meola and Rakocevic-Stojanovic.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Diabetes Metab Res Rev. 2014 Feb;30(2):96-102
pubmed: 24123849
Nat Genet. 2010 Apr;42(4):295-302
pubmed: 20190752
Biomed Res Int. 2013;2013:391821
pubmed: 23586035
Autoimmun Rev. 2012 May;11(6-7):A531-7
pubmed: 22155196
J Neurol. 2017 Sep;264(9):1899-1908
pubmed: 28756605
Am J Pathol. 2011 Nov;179(5):2475-89
pubmed: 21889481
J Neuromuscul Dis. 2017;4(1):89-92
pubmed: 28106565
J Neurol. 2020 Sep;267(9):2744-2746
pubmed: 32647901
J Neuromuscul Dis. 2018;5(4):461-469
pubmed: 30248060
J Ocul Pharmacol Ther. 2007 Oct;23(5):403-20
pubmed: 17900234
Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10746-50
pubmed: 9724775
J Neurol. 2021 Jul;268(7):2441-2449
pubmed: 33507372
Neuromuscul Disord. 2015 Feb;25(2):149-52
pubmed: 25443993
J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):355-367
pubmed: 34970859
Mult Scler Relat Disord. 2018 Aug;24:117-119
pubmed: 29982108
Neurology. 2003 Feb 25;60(4):657-64
pubmed: 12601109
Reumatismo. 2018 Oct 03;70(3):133-145
pubmed: 30282439
J Intern Med. 2015 Oct;278(4):369-95
pubmed: 26212387
J Neurol Neurosurg Psychiatry. 2009 Nov;80(11):1293-5
pubmed: 19864666
Am J Hum Genet. 2004 Jun;74(6):1309-13
pubmed: 15114529
Reumatologia. 2018;56(4):243-248
pubmed: 30237629
Acta Myol. 2020 Dec 01;39(4):222-234
pubmed: 33458578
J Neurol. 2013 Oct;260(10):2497-504
pubmed: 23807151
Neuromuscul Disord. 2018 Oct;28(10):825-827
pubmed: 30194026
Clin Neurol Neurosurg. 2012 Dec;114(10):1358-60
pubmed: 22502787
J Clin Neurol. 2013 Apr;9(2):130-2
pubmed: 23626652
Eur J Hum Genet. 2020 Dec;28(12):1743-1752
pubmed: 32733071
Proc Biol Sci. 2011 Dec 22;278(1725):3617-24
pubmed: 21976687
Neuromuscul Disord. 2018 Oct;28(10):878-880
pubmed: 30197184
Neurol Sci. 2011 Dec;32(6):1249-50
pubmed: 21948056
Neuromuscul Disord. 2021 Aug;31(8):681-694
pubmed: 34244019

Auteurs

Stojan Peric (S)

Neurology Clinic, University Clinical Center of Serbia, Belgrade, Serbia.
Faculty of Medicine, University of Belgrade, Belgrade, Serbia.

Jelena Zlatar (J)

Faculty of Medicine, University of Belgrade, Belgrade, Serbia.

Luka Nikolic (L)

Faculty of Medicine, University of Belgrade, Belgrade, Serbia.

Vukan Ivanovic (V)

Neurology Clinic, University Clinical Center of Serbia, Belgrade, Serbia.

Jovan Pesovic (J)

Center for Human Molecular Genetics, Faculty of Biology, University of Belgrade, Belgrade, Serbia.

Ivana Petrovic Djordjevic (I)

Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Cardiology Clinic, University Clinical Center of Serbia, Belgrade, Serbia.

Svetlana Sreckovic (S)

Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Anaesthesiology Clinic, University Clinical Center of Serbia, Belgrade, Serbia.

Dusanka Savic-Pavicevic (D)

Center for Human Molecular Genetics, Faculty of Biology, University of Belgrade, Belgrade, Serbia.

Giovanni Meola (G)

Department of Neurorehabilitation Sciences, Casa Di Cura del Policlinico, Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.

Vidosava Rakocevic-Stojanovic (V)

Neurology Clinic, University Clinical Center of Serbia, Belgrade, Serbia.
Faculty of Medicine, University of Belgrade, Belgrade, Serbia.

Classifications MeSH